Helpful resources for you and your patients

The following are helpful resources for healthcare professionals as well as the patients you care for.

RESOURCES FOR HEALTHCARE PROFESSIONALS

Treatment Form

The NUPLAZID® (pimavanserin) Treatment Form serves as a prescription for NUPLAZID and enrolls your patients into NUPLAZIDconnect™. To learn more, visit NUPLAZIDconnect™.

Download

Dosing Guide

The Dosing Guide gives you complete information on dosing and administration for NUPLAZID.

Download

A Closer Look: Proposed Mechanism of Action for NUPLAZID

Watch this video for the proposed mechanism of action for NUPLAZID. The precise mechanism of action of NUPLAZID in the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis is unknown.

Running time 5:24

PDP Proposed Mechanism of Disease and Mechanism of Action for NUPLAZID

Watch this video to see more of how the proposed mechanism of action for NUPLAZID relates to what a patient with Parkinson’s disease psychosis may experience.

Running time 8:12


Conversation Starter

The “Start the Conversation” brochure includes a short questionnaire that helps initiate a dialogue about PD psychosis with your patients and their caregivers.

Download


RESOURCES FOR YOUR PATIENTS & CAREGIVERS

Disease Education Fact Sheet

The Disease Education Fact Sheet, “Understanding Parkinson’s Disease Psychosis,” is designed to give your patients an overview of Parkinson’s disease psychosis and is also available in 8 different languages.

Download

Patient Brochure

The Patient Brochure, “Getting Started With NUPLAZID,” is designed to give your patients and their caregivers more detailed information about NUPLAZID.

Download
NUPLAZIDconnect™ makes it easy to get patients started on treatment

RESOURCES FOR LONG-TERM CARE

Long-Term Care Service Request Form

The NUPLAZID Long-Term Care Service Request Form allows your facility to request services for residents who are starting on NUPLAZID. Services include benefits investigation, support in the prior authorization/appeals process, and information on financial assistance programs.

Download

Distribution Fact Sheet

The NUPLAZID Distribution Fact Sheet provides a product overview of NUPLAZID, including administration, storage and handling; and lists the available fulfilment options to your facility when placing an order.

Download

LTC Documentation & Monitoring Tips

This guide is designed to assist your facility in following the prescribing and monitoring requirements outlined by Centers for Medicare & Medicaid Services (CMS) when working with residents receiving NUPLAZID.

Download

Beyond Motor Symptoms eBook

“Understanding Hallucinations and Delusions in Parkinson’s Disease” is a discussion guide for healthcare professionals, residents, and caregivers to help identify, manage, and treat Parkinson’s disease psychosis.

Download

Treating Hallucinations and Delusions associated with Parkinson’s Disease Psychosis in the Long-Term Care Setting

Dr. Kellogg and Dr. Saffel discuss hallucinations and delusions associated with Parkinson’s disease psychosis and its treatment in the Long-term Care setting in an interactive newsletter.

Download


SCIENTIFIC PRESENTATIONS

Treating the Hallucinations and Delusions Associated With Parkinson’s Disease Psychosis

In this recording of a live event, Dr. Stuart Isaacson, Director, Parkinson’s Disease and Movement Disorders Center of Boca Raton, hosts a panel discussion about Parkinson’s disease psychosis and NUPLAZID with Dr. Henry Nasrallah and Dr. Daniel Kremens.


Perspectives on Hallucinations & Delusions Associated With Parkinson’s Disease Psychosis: A Video

This comprehensive video features the perspectives of Dr. Jason Kellogg, psychiatrist, and Dr. Claire Henchcliffe, Movement Disorder Specialist, on the use of NUPLAZID for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.


Treating Hallucinations and Delusions Associated With Parkinson’s Disease Psychosis

Dr Meltzer and Dr Hermanowicz discuss hallucinations and delusions associated with Parkinson’s disease psychosis and its treatment in an interactive newsletter.

Download

Important Safety Information for NUPLAZID (pimavanserin) 17-mg Tablets

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson's disease psychosis.

Contraindication: NUPLAZID is contraindicated in patients with a history of hypersensitivity reaction to pimavanserin or any of its components. Reactions have included rash, urticaria, tongue swelling, circumoral edema, and throat tightness.

QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics. NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

Adverse Reactions: The most common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).

Drug Interactions: Strong CYP3A4 inhibitors (eg, ketoconazole) increase NUPLAZID concentrations. Reduce the NUPLAZID dose by one-half. Strong CYP3A4 inducers may reduce NUPLAZID exposure, monitor for reduced efficacy. Increase in NUPLAZID dosage may be needed.

Renal Impairment: No dosage adjustment for NUPLAZID is needed in patients with mild to moderate renal impairment. Use of NUPLAZID is not recommended in patients with severe renal impairment.

Hepatic Impairment: Use of NUPLAZID is not recommended in patients with hepatic impairment. NUPLAZID has not been evaluated in this patient population.

Pregnancy: Use of NUPLAZID in pregnant women has not been evaluated and should therefore be used in pregnancy only if the potential benefit justifies the potential risk to the mother and fetus.

Pediatric Use: Safety and efficacy have not been established in pediatric patients.

Dosage and Administration

Recommended dose: 34 mg per day, taken orally as two 17-mg tablets once daily, without titration.

Indication

NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

To report SUSPECTED ADVERSE REACTIONS, contact ACADIA Pharmaceuticals Inc. at 1-844-4ACADIA (1-844-422-2342) or FDA at www.fda.gov/medwatch , or call 1-800-FDA-1088.

Please read the full Prescribing Information including Boxed WARNING.

This website is intended for use by US residents.

Important Safety Information for NUPLAZID (pimavanserin) 17-mg Tablets

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson's disease psychosis.

Contraindication: NUPLAZID is contraindicated in patients with a history of hypersensitivity reaction to pimavanserin or any of its components. Reactions have included rash, urticaria, tongue swelling, circumoral edema, and throat tightness.

QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics. NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

Adverse Reactions: The most common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).

Drug Interactions: Strong CYP3A4 inhibitors (eg, ketoconazole) increase NUPLAZID concentrations. Reduce the NUPLAZID dose by one-half. Strong CYP3A4 inducers may reduce NUPLAZID exposure, monitor for reduced efficacy. Increase in NUPLAZID dosage may be needed.

Renal Impairment: No dosage adjustment for NUPLAZID is needed in patients with mild to moderate renal impairment. Use of NUPLAZID is not recommended in patients with severe renal impairment.

Hepatic Impairment: Use of NUPLAZID is not recommended in patients with hepatic impairment. NUPLAZID has not been evaluated in this patient population.

Pregnancy: Use of NUPLAZID in pregnant women has not been evaluated and should therefore be used in pregnancy only if the potential benefit justifies the potential risk to the mother and fetus.

Pediatric Use: Safety and efficacy have not been established in pediatric patients.

Dosage and Administration

Recommended dose: 34 mg per day, taken orally as two 17-mg tablets once daily, without titration.

Indication

NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

To report SUSPECTED ADVERSE REACTIONS, contact ACADIA Pharmaceuticals Inc. at 1-844-4ACADIA (1-844-422-2342) or FDA at www.fda.gov/medwatch , or call 1-800-FDA-1088.

Please read the full Prescribing Information including Boxed WARNING.

This website is intended for use by US residents.